Ekf Diagnostics Share Price (EKF)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Ekf Diagnostics Holdings Plc	LSE:EKF	London	Ordinary Share	GB0031509804	ORD 1P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	0.00	0.0%	32.90	4,690	10:43:31

Bid Price		Offer Price	High Price	Low Price	Open Price
32.70		33.50

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Health Care Equipment & Services	81.84	21.44	3.47	9.5	150

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
10:12:13	O	2,382	33.5845	GBX

Related Shares
Smith & Nephew (SN.), Convatec (CTEC), Salvarx (SALV), Sensyne Health (SENS)

Ekf Diagnostics (EKF) Latest News

Ekf Diagnostics News

Date	Time	Source	Headline
29/6/2022	16:41	UKREG	EKF Diagnostics Holdings PLC Second Price Monitoring Extn
29/6/2022	16:36	UKREG	EKF Diagnostics Holdings PLC Price Monitoring Extension
28/6/2022	15:34	UKREG	EKF Diagnostics Holdings PLC Holding(s) in Company
22/6/2022	16:36	UKREG	EKF Diagnostics Holdings PLC Price Monitoring Extension
21/6/2022	07:00	UKREG	EKF Diagnostics Holdings PLC Director/PDMR Shareholding
20/6/2022	18:26	ALNC	IN BRIEF: EKF Diagnostics distributes 9.1 million Verici shares
20/6/2022	07:00	UKREG	EKF Diagnostics Holdings PLC Distribution of shares in Verici Dx plc
13/6/2022	17:01	ALNC	TRADING UPDATES: Steppe Cement annual profit rises, withholds payout
13/6/2022	07:00	UKREG	EKF Diagnostics Holdings PLC Update on strong cash position
09/6/2022	20:04	ALNC	IN BRIEF: EKF Diagnostics launches digital connectivity solution

More Ekf Diagnostics News

Ekf Diagnostics Investors Ekf Diagnostics Takeover Rumours

Ekf Diagnostics (EKF) Share Charts 1 Year Ekf Diagnostics Chart
1 Month Ekf Diagnostics Chart	Intraday Ekf Diagnostics Chart

Ekf Diagnostics (EKF) Discussions and Chat

Ekf Diagnostics Forums and Chat

Date	Time	Title	Posts
03/7/2022	12:45	EKF Diagnostics for income and growth - A healthy, reliable combination!	2,845
24/9/2020	22:56	EKF Diagnostics - Growth by acquisition, expertise and special relationships	1,376
27/7/2011	06:35	EKF Diagnostics – Growth by acquisition, expert knowledge and special relationsh	7
25/7/2011	14:22	EKF Diagnostics	209
13/7/2010	21:15	EFK DIAGNOSTICS	6

Add a New Thread

Ekf Diagnostics (EKF) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
09:12:14	33.58	2,382	799.98	O
09:11:24	32.70	2,065	675.26	O
09:04:13	33.58	29	9.74	O
08:05:04	33.80	100	33.80	O
07:18:35	33.76	112	37.81	O

View all Ekf Diagnostics trades in real-time

Ekf Diagnostics (EKF) Top Chat Posts

Date	Subject
05/7/2022 09:20	Ekf Diagnostics Daily Update: Ekf Diagnostics Holdings Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 32.90p. Ekf Diagnostics Holdings Plc has a 4 week average price of 30p and a 12 week average price of 30p. The 1 year high share price is 86.80p while the 1 year low share price is currently 30p. There are currently 454,930,564 shares in issue and the average daily traded volume is 215,317 shares. The market capitalisation of Ekf Diagnostics Holdings Plc is £149,672,155.56. Read Full Thread Reply
01/7/2022 14:23	wan: 'On plan' news - Industry News: EKF to highlight specific glycemic control marker at AACC 2022 EKF Diagnostics exhibiting range of tests and analyzers on Booth #3637 30 Jun 2022 EKF Diagnostics, a global in vitro diagnostics company, will be at the 2022 AACC Clinical Lab Expo, Chicago IL, July 26-28, exhibiting its range of laboratory and point-of-care diagnostics products on Booth #3637. This includes the FDA cleared Lucica® Glycated Albumin-L test kit, manufactured by Asahi Kasei Pharma Corporation and sold exclusively in the U.S. by EKF. A specific, quantitative test for glycated albumin, it is one of the most widely published methods worldwide used for the intermediate term monitoring of glycemic control in diabetes patients. Lucica® Glycated Albumin-L is an enzymatic methodology for use on compatible clinical chemistry analyzers with open channel capability, making it accurate and cost-effective to perform. It determines both glycated albumin and total albumin in separate reactions and the results are expressed as a ratio (%), minimizing differences in albumin concentrations between patients. Lucica® is also standardized to an established reference material. “The Lucica® Glycated Albumin-L is sold exclusively by EKF Diagnostics in the U.S. and complements our existing diabetes product range, offering its own utility as a specific, intermediate glycemic control marker,” said Shane O’Neill, Global Director of Scientific Affairs, EKF Diagnostics. Alongside its range of clinical chemistry tests and diagnostics analyzers, also available to view on EKF’s Booth at AACC will be its newly launched EKF Link digital connectivity solution. The downloadable software package offers secure management of point-of-care (POC) analyzers and associated data on one centralized platform. This delivers essential digital connectivity with traceability that is increasingly required for safe, secure, and effective POC testing using analyzers in many differing locations. EKF Link middleware is an open and flexible solution which can be interfaced to all vendors’ POC analyzers, including EKF’s own portfolio, to enable real-time remote management of data, including patient test results, QC results, operator management, and analyzer configuration. The user-friendly software allows POC analyzers to connect to a hospital or laboratory’s IT system, enabling data transfer from the remote analyzers for subsequent processing. This provides hospitals, laboratories, and clinicians with the functionality to manage and evaluate their patient and operator data easily and securely. EKF’s portfolio of POC diagnostic devices includes Hemo Control and DiaSpect Tm hemoglobin analyzer ranges, as well as Quo-Lab and Quo-Test HbA1c analyzers. All of these can now be digitally connected from anywhere and securely accessed remotely at any time using EKF Link, thereby enhancing their capabilities. hTTps://www.selectscience.net/industry-news/ekf-to-highlight-specific-glycemic-control-marker-at-aacc-2022/?artID=57786 Recall from the EKF Link RNS - The development and launch of EKF Link has been driven by customer demand and designed in partnership with hospital POC managers to ensure the software meets their specific needs. EKF Link provides the Company with improved competitive positioning for future POC contract tenders and new accounts, and increases the attractiveness of the EKF product portfolio to existing customers against currently available technologies. Mike Salter, CEO, of EKF Diagnostics said: "As part of our strategy to enhance our POC analyser portfolio and technology offering, we are pleased to announce that we have successfully launched EKF Link enabling practitioners to analyse their patients' results remotely, easily and securely. EKF Link provides our POC diagnostic devices with a connectivity advantage which positions us well for tenders and new accounts. This is particularly true in Europe and North America, where a connectivity solution is commonly a part of the specification. EKF Link has the added benefit that it can be installed wherever it is needed, on a PC or a central server, allowing hospitals and laboratories, technicians and clinicians to access results from various settings, reducing workload whilst increasing the security of handling patient data. "This new product launch shows our responsiveness to our customer base and increasing demand for data management capabilities. It extends the utility of our installed instrument base and provides EKF with a key advantage for further new business opportunities." hTTps://www.ekfdiagnostics.com/launch-of-ekf-link.html Read Full Thread Follow Reply
31/5/2022 05:29	wan: EKF Diagnostics : launches middleware connectivity solution for POC analyzers and data management 05/30/2022 EKF Diagnostics announces the launch of its newEKF Link digital connectivity solution for the secure management of point-of-care (POC) analyzers and associated data on one centralized platform. An open, flexible solution, EKF Link middleware can be interfaced to all vendors' POC analyzers, including EKF's own portfolio, to enable real-time remote management of data, such as patient test results, QC results, operator management and analyzer configuration. "We designed EKF Link working together with hospital POC managers to ensure that our new middleware connectivity solution would meet their specific needs for a single, comprehensive and flexible platform to centrally manage all of their POC analyzers plus data generated," said Jo Nicol, Head of IT Solutions, EKF Diagnostics. "Our new EKF Link software delivers this essential digital connectivity with traceability that is increasingly required for safe, secure and effective POC testing using analyzers in many differing locations." Full release - hTTps://www.ekfdiagnostics.com/ekf-launches-poc-connectivity-solution.html Connect all of your analyzers on one software platform EKF Link is a middleware solution for healthcare providers to manage all of their Point of Care analyzers and the generated data on one centralized platform. EKF Link is a flexible, open solution that can be interfaced to any vendor’s Point of Care analyzer to permit the real-time management of data including patient test results, QC results, operator management and analyser configuration. EKF Link enables the transfer of data from the analyzer to the hospital or laboratory database for subsequent processing. hTTps://www.ekfdiagnostics.com/ekf-link.html Read Full Thread Follow Reply
03/5/2022 08:04	wan: It would appear that some with vastly more insight and knowledge, namely Harwood Capital LLP and Harwood Capital Management, by raising their stake in EKF to 29.04%, can also see the much bigger picture. I repeat, in part, from a previous post - EKF was in fact trading at around these levels in share price terms for all of 2019 and the early part of 2020, but that was before the pandemic, and before the current level of investment and implementation of EKF's Growth Strategy. So, EKF have been pared back in share price terms, to pre-pandemic when the growth prospects were different (not bad), but arguably the previous and indeed new non-COVID prospects, new skills, and new customers, are not comparable to the pre-pandemic period. But unless you take a longer term view, then the fall in the share price is all you have to talk about! When you are unfortunately dealing with diagnosing and managing diseases, such as diabetes, that process does not stop, or indeed slow down. Read Full Thread Follow Reply
28/4/2022 10:42	wan: I am not going to rise to being ridiculed etc, especially when my investment horizons and rationale are clearly very different. EKF was in fact trading at around these levels in share price terms for all of 2019 and the early part of 2020, but that was before the pandemic, and before the current level of investment and implementation of EKF's Growth Strategy. So, EKF have been pared back in share price terms, to pre-pandemic when the growth prospects were different (not bad), but arguably the non-COVID prospects, new skills, and new customers, are not comparable to the pre-pandemic period. But unless you take a longer term view, then the share price is all you have to talk about! Read Full Thread Follow Reply
15/4/2022 13:41	james188: Wan, It is pretty much the same story as for SBI, although EKF is more mature and has a broader offering. Both companies seized opportunities created by the pandemic, which more than compensated for the impact on their core businesses. They now need to fill the hole created by the inevitable fall off in COVID related revenues. I suspect that the EKF share price will remain in the doldrums until there is tangible evidence that the hole is filled. Personally, I expect that to happen and I may well add next week when the price could well fall further. One worry I have is that EKF could be taken private. Christopher Mills has form in this respect. Read Full Thread Follow Reply
15/4/2022 10:57	wan: Stoxman...My thoughts, for what they are worth. With the general cloud hanging over the growth/biotech sector, perhaps exemplified by the fact that there is apparently a record £1.9tn on deposit in the UK at a time when deposit rates are at a record low, it's definitely risk off, but one could also argue that there is potentially a lot of dry powder in the wings. For those of us still holding the extended family of EKF stocks, on the one hand we are still better off than we were without the in-specie shares, but the overall performance thus far is disappointing to say the least. With regard to Verici in particular, clearly some investors preferred to sell rather than hold post the lock-up period, and given the dire performance, it appears they have been proven right so far. And it would also appear that the performance of Trellus is perhaps indicating that a similar post lock-up situation could occur starting next month. Personally speaking, I cooled on Trellus a while back given that they appear to be delayed, and indeed the number of companies focusing on similar/overlapping areas is presenting for a huge amount of competition. Given the unrelenting selling in Verici post lock-up, not to mention the overall performance across the holdings, and indeed the market backdrop, going forwards one wonders if the spin-off model has any immediate candidates/legs, or will indeed follow similar paths, especially if Trellus follows similar price action to Verici. In my view, Verici is in a more advanced and stronger position. There are larger players that could not only accelerate commercialisation, but that are arguably in need Verici's differentiated and litigation free products, which are underpinned by extensive scientific research and strong IP. At the very least, I am thus expecting partnerships, and I would not exclude Verici being acquired outright. A partnership deal, or a catalyst breakthrough in any one of the family could have a positive effect on the others, but we have been expecting that from Renalytix for quite some time, and clearly analysts have finally run out of patience with the management at Renalytix, which is not completely unfair, but I can see both sides of the argument. Again, in my view, it's far too early to judge the new management team, but clearly the market does not like the current forecasts, as exampled below, albeit it I think James had already highlighted such coverage a few weeks ago, so I am not sure how up to date/relevant it actually is - Some EKF Diagnostics Holdings plc (LON:EKF) Analysts Just Made A Major Cut To Next Year's Estimates By Simply Wall St Published April 14, 2022 hTTps://simplywall.st/stocks/gb/healthcare/aim-ekf/ekf-diagnostics-holdings-shares/news/some-ekf-diagnostics-holdings-plc-lonekf-analysts-just-made What I did find interesting in the above piece, was the graph, which clearly shows the expected revenue decline. Nonetheless, when you factor-out the COVID related bump, revenue growth in 2023 is quite a lot higher than pre-pandemic revenues, and overall the forecast is on a not too shabby upward trajectory. According to the chart, revenues and other financial metrics for 2024 are forecast to be similar to the COVID-boosted revenues for 2021. If we were to assume that a similar share price can be achieved to the peak in 2021 of over 80p, some would suggest that, for the patient investor, the current share price is offering a decent entry point and a dividend yield of over 3%. An important difference to consider though, is that the non-COVID related growth in revenues will be far more sustainable! I am hopeful that managements guidance has been conservative (EKF's Growth Strategy indicated such with regard to fermentation), as obviously it would be much better to resume a period of beating analysts expectations, especially with revenue increases that are sustainable. Read Full Thread Follow Reply
13/4/2022 23:15	buywell3: wan Ref your reply about buybacks shown below Share buybacks only make sense when the NAV/share is above the current share price and therefore shares are being bought at a discount to the NAV/share. Which then could in some cases be like the company buying back its own debt at 50p in the £1. As we stand here the advfn NAV/share is BELOW the current share price so the board are literally using shareholders money to buy £1 coins for £1.50 each. advfn have the NAV at circa 20p and the buybacks have been at twice the price or 4 times the price if Net Tangible Asset Value per share were used Net Tangible Asset Value PS * 11.26 p Net Asset Value PS 20.42 p This in effect is cash wasteful and could lead to the share price falling due to the market seeing such an action as a waste of valuable capital reserves in prevailing and deteriorating market conditions . Worthy of consideration ? ---------------------------------------- wan5 Apr '22 - 09:13 - 2616 of 2648 0 1 0 Buywell...5,950,000 to be precise! I duly noted SBI's results. There is an important and fundamental difference regarding the buyback. SBI's recent acquisition, along with future earnout payments are all payable in cash. Whereas EKF's recent acquisition was satisfied by the issue of new ordinary shares at 80p+ to the value of £10mn. A similar amount of shares are now being bought back at 40p+ and held in treasury. And as my post 2612 above alludes to, the treasury shares could potentially be utilised to satisfy the ADL earnouts. And wouldn't it be good business if the shares at the various earnout anniversaries are materially higher than current buybacks, potentially meaning in my book that the treasury shares were even better value (to EKF and its investors), bearing in mind that the price per share issued to satisfy any earnout payments will be calculated using the average mid-market closing price of EKF’s shares for the five working days immediately preceding the issuance date of such shares. Obviously we don't know where the share price might be come October (1st ADL anniversary), but we know there will be news flow between now and October and we know there are various developments in the pipeline, including further execution on the Growth Strategy. So, for the purpose of an example and perhaps only for those with a positive and longer term view on EKF. Imagine a scenario where earnouts are calculated at an average mid-market closing price of EKF’s shares at 60p+ (being conservative!) when EKF are holding shares in treasury bought at 40p+. Food for thought! Read Full Thread Follow Reply
05/4/2022 09:13	wan: Buywell...5,950,000 to be precise! I duly noted SBI's results. There is an important and fundamental difference regarding the buyback. SBI's recent acquisition, along with future earnout payments are all payable in cash. Whereas EKF's recent acquisition was satisfied by the issue of new ordinary shares at 80p+ to the value of £10mn. A similar amount of shares are now being bought back at 40p+ and held in treasury. And as my post 2612 above alludes to, the treasury shares could potentially be utilised to satisfy the ADL earnouts. And wouldn't it be good business if the shares at the various earnout anniversaries are materially higher than current buybacks, potentially meaning in my book that the treasury shares were even better value (to EKF and its investors), bearing in mind that the price per share issued to satisfy any earnout payments will be calculated using the average mid-market closing price of EKF’s shares for the five working days immediately preceding the issuance date of such shares. Obviously we don't know where the share price might be come October (1st ADL anniversary), but we know there will be news flow between now and October and we know there are various developments in the pipeline, including further execution on the Growth Strategy. So, for the purpose of an example and perhaps only for those with a positive and longer term view on EKF. Imagine a scenario where earnouts are calculated at an average mid-market closing price of EKF’s shares at 60p+ (being conservative!) when EKF are holding shares in treasury bought at 40p+. Food for thought! Read Full Thread Follow Reply
05/4/2022 08:10	buywell2: 6M buybacks and only another 3M left is that not correct Then quite a long wait for the next tranche if it gets the nod Interestingly SBI have not announced an initial/interim buyback program like EKF What say you wan ? 05 Apr 2022 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares 04 Apr 2022 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares 01 Apr 2022 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares 31 Mar 2022 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares 30 Mar 2022 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares 29 Mar 2022 7:01 am RNS Factsheet EKF Diagnostics Hldg (EKF) Share Buyback Programme 7:00 am RNS Factsheet EKF Diagnostics Hldg (EKF) Final Results Read Full Thread Follow Reply
30/11/2021 08:04	wan: Published Nov. 29, 2021 Dive Brief: The emergence of a new COVID-19 variant, named omicron (B.1.1.529), is putting pressure on diagnostics manufacturers who test for the presence of SARS-CoV-2 to ensure its results are not impacted. Thermo Fisher Scientific, Qiagen and Lucira Health were quick to claim their tests can detect the emerging variant. hTTps://www.medtechdive.com/news/omicron-variant-not-issue-some-covid-test-makers-say/610612/ PCR testing and sequencing are thus likely to see an notable increase in demand. Moving on to EKF as a whole (beyond COVID testing), it's worth considering the fact that EKF is not standing still, albeit we will know more about progress and delivery of the Growth Strategy in due course. In this regard, it's worth recalling Singer's headlines to its research note on EKF from July - EKF recently unveiled a strategy for driving growth in the business over the next few years. It will be led by a refreshed executive management team and board, building on renewed strength in the core business and opportunities in developing wider contract development and manufacturing activities. Accretive bolt-on acquisitions will also be considered, all funded by the current strong net cash position of the group. Overall, the ambition is to deliver sustainable double-digit EBITDA growth into the medium term. This note takes a detailed look at the growth drivers and opportunities now in prospect. In addition to introducing conservative formal FY22 & FY23 estimates for the first time, we also look at a range of potential scenarios, one of which shows how EBITDA could reach £45.9m by FY24. Putting that on a multiple of 13- 15x implies a potential Enterprise Value of £597-688m, against a current EV of £314m. Successful delivery should therefore lead to material value creation. (END) Interestingly, the following came onto my radar today and uses a measure that implies EKF is currently undervalued by 33% with a current share price on 74p versus a fair value of £1.11 - Compared to the current share price of UK£0.7, the company appears quite good value at a 33% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent. hTTps://simplywall.st/stocks/gb/healthcare/aim-ekf/ekf-diagnostics-holdings-shares/news/an-intrinsic-calculation-for-ekf-diagnostics-holdings-plc-lo Read Full Thread Follow Reply

Ekf Diagnostics share price data is direct from the London Stock Exchange

Advertise Here

Your Recent History

LSE

EKF

Ekf Diagno..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20220705 11:54:17